|Description||CH5137291 is a potent androgen receptor (AR) pure antagonist which did not produce the agonist metabolite with AR nuclear translocation-inhibiting activity. It inhibits the growth of castration-resistant prostate cancer cells. It offers a novel therapeutic approach against major types of castration-resistant prostate cancers.|
|Solubility||10 mM in DMSO|
|Application||CH5137291 offers a novel therapeutic approach against major types of castration-resistant prostate cancers.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Boiling Point||654.4±65.0 °C | Condition: Press: 760 Torr|
|Density||1.65±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
ARN-509, also known as JNJ-56021927, is an androgen receptor antagonist with potential antineoplastic activity. ARN-509 binds to AR in target tissues thereby p...
Bicalutamide is a non-steroidal androgen receptor (AR) antagonist with IC50 of 0.16 μM.
BX341, also known as bifluranol, is a new fluorinated bibenzyl anti-androgen and one of a series of bibenzyls designed to present some of the hormonal propertie...
MK-3984 is a androgen receptor modulators. It can be used for the prevention and treatment of muscle wasting associated with cancer.
Spironolactone is a potent antagonist of the androgen receptor with IC50 of 77 nM.
RAD140, an effective non-steroidal selective androgen receptor modulator, could probably stimulate the increasing of muscle and also has been found to have pote...
RU 58841 is a new non-steroidal antiandrogen which has potential for use in treating androgen-dependent skin disorders such as acne, hirsutism and androgen-depe...
Fasobegron acts a β3-adrenoreceptor agonist.
Andarine is a selective non-steroidal androgen receptor (AR) agonist with Ki of 4 nM, tissue-selective for anabolic organs.
Enzalutamide is an androgen-receptor (AR) antagonist with IC50 of 36 nM. It inhibits the activity of prostate cancer cell Ars, which over expressed in prostate ...
A steroidal antiandrogen drug
CH5137291 is a potent androgen receptor (AR) pure antagonist which did not produce the agonist metabolite with AR nuclear translocation-inhibiting activity. It ...
ASC-J9 is an AR degradation enhancer, suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen rece...
AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity. AZD3514 is being evaluated in a Phase I clinical trial in patie...
JNJ-26146900 is a selective, nonsteroidal androgen receptor modulator with tissue-selective activity in rats. It can bind to the rat AR with a Ki of 400nM and a...
ORM-15341, an androgen receptor antagonist, could have potential effect against prostate cancer and commonly found as an active main metabolite of ODM-201. IC50...
LGD-4033, also known as VK5211 and Ligandrol, is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wast...
MI-136, with the potential to treat refractory prostate cancer, inhibits DHT-induced expression of androgen receptor (AR) target genes. In vitro: Treatment with...
LGD-2226 is a selective androgen receptor modulator used in the treatment of muscle wasting and osteoporosis, shows to have an anabolic effect on muscle and bon...
ODM-201 is a new-generation, potent and selective androgen receptor (AR) inhibitor which is potential useful for treatment of castration-resistant prostate canc...